SAN FRANCISCO--(BUSINESS WIRE)--
Invitae Corporation (NYSE: NVTA), a genetic information company,
announced today the pricing of its initial public offering of 6,350,000
shares of its common stock at an initial offering price of $16.00 per
share, for total gross proceeds of $101.6 million before deducting
underwriting discounts and commissions and other offering expenses. The
shares of Invitae’s common stock are expected to begin trading on the
New York Stock Exchange under the symbol “NVTA” on February 12, 2015.
All of the shares in the offering are being offered by Invitae. The
offering is expected to close on or about February 18, 2015, subject to
customary closing conditions. In addition, Invitae has granted the
underwriters a 30-day option to purchase up to an additional 952,500
shares of common stock at such offering price, less customary
underwriting discounts and commissions.
J.P. Morgan Securities LLC is acting as the sole book-running manager
for the offering. Cowen and Company, LLC and Leerink Partners LLC are
acting as co-managers.
Registration statements relating to these securities have been filed
with the Securities and Exchange Commission and became effective on
February 11, 2015. The offering is being made only by means of a
prospectus. Copies of the final prospectus relating to and describing
the terms of the offering, when available, may be obtained from J.P.
Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Invitae
Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic
information into mainstream medical practice to improve the quality of
healthcare for billions of people. Currently focused on hereditary
cancers, Invitae’s goal is to aggregate most of the world’s genetic
tests into a single service with higher quality, faster turnaround time
and lower price than many single-gene tests today. The company currently
provides a single diagnostic test comprising over 200 genes for a
variety of genetic disorders associated primarily with cancer, but also
covering cardiology, hematology, neurology and pediatrics.
Source: Invitae Corporation
Contact:
Katherine Stueland
pr@invitae.com
415.254.1233